The Words are right here

Discussion in 'Sunovion' started by Anonymous, Jan 20, 2012 at 4:30 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    "To meet the needs of the market, Takeda will also shift from a product portfolio centered on mature, high selling products to a more diverse portfolio focused on new products. The combined company has an active commercial presence in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management."

    This was taken from Press Release of Takeda, two days ago.

    Real Simple.

    They have the rights to Alvesco outside US.
    Takeda has rights to Daliresp. Forest sells in US.

    The rumors are true. Takeda will be branching out into Allergy and Respiratory Diseases.

    Omnaris, Alvesco, Omnaris HFA will all be theirs.

    Sunovion had to pay certain milestone payments. Once money is worked out, GOOD BYE OMNARIS SALES FORCE.

    XOPENEX HFA WILL GO TO Brovana.

    TIME FRAME IS QUICK.

    GET RESUMES OUT NOW!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
    WE ARE BEING LIED TO AND FUCKED WITH!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
     

  2. Anonymous

    Anonymous Guest

    Ran into my takeda rep today and they mentioned that as well. Time to pack up!